Benzinga | Nov 6, 2020 05:16AM EST

SVB Leerink Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $197

SVB Leerink analyst Joseph Schwartz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $214 to $197.